mTOR inhibitors for hepatocellular cancer: A forward-moving target

Expert Review of Anticancer Therapy

Volumn 9, Issue 2, 2009, Pages 247-261

  Treiber, Gerhard ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Everolimus; Hepatocellular cancer; Inhibitor; Mammalian target of rapamycin; Sirolimus; Temsirolimus

Indexed keywords

AFINITOR; BEVACIZUMAB; CALCINEURIN INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; S6 KINASE; SOMATOMEDIN; SORAFENIB; TACROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE;

ABNORMAL LABORATORY RESULT; ANOREXIA; BIPOLAR DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; EYE TOXICITY; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL; NAUSEA; NEUTROPENIA; NONHUMAN; PNEUMONIA; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS REACTIVATION; VOMITING; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASES;

EID: 64349104998     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.2.247     Document Type: Review

References (48)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
2. El-Serag HB, Marrero JA, Rudolph L et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134, 1752-1763 (2008).
3. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig. Dis. 19, 311-323 (2001).
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48(Suppl. 1), S20-S37 (2008).
5. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (2006).
6. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebocontrolled trial (SHARP trial). J. Clin. Oncol. 25, LBA1 (2007).
7. Cheng A, Kang Y, Chen Z et al. Randomized Phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 26, (2008) (Abstract 4509).
8. Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J. Gastroenterol. 13, 5845-5856 (2007).
9. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72(Suppl. 1), 30-44 (2007).
10. Kopelovich L, Fay JR, Sigman CC et al. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev. 16, 1330-1340 (2007).
11. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25, 6347-6360 (2006).
12. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348 (2004).
13. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 25, 6436-6446 (2006).
14. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671-688 (2006).
15. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007)
16. Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Adv. Exp. Med. Biol. 587, 309-327 (2006).
17. Seeliger H, Guba M, Kleespies A et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 26, 611-621 (2007).
18. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17, 487-494 (2006).
19. Easton JB, Kurmasheva RT, Houghton PJ. IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 9, 153-155 (2006).
20. Sahin F, Kannangai R, Adegbola O et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin. Cancer Res. 10, 8421-8425 (2004).
21. Sieghart W, Fuereder T, Schmid K et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83, 425-432 (2007).
22. Baba HA, Wohlschlaeger J, Cicinnati VR et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. DOI: 10.1111/ j.1478-3231.2008.01798.x (2008) (Epub ahead of print).
23. Villanueva A, Chiang DY, Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6), 1972-1983 (2008).
24. Schmitz KJ, Wohlschlaeger J, Lang H et al. Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 48, 83-90 (2008).
25. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs 14, 313-328 (2005).
26. Huynh H, Chow KP, Soo KC et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. DOI: 10.1111/j.1582-4934.2008.00364.x (2008) (Epub ahead of print).
27. Rizell M, Lindner P. Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res. 25, 789-793 (2005).
28. Schumacher G, Oidtmann M, Rueggeberg A et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J. Gastroenterol. 11, 1420-1425 (2005).
29. Semela D, Piguet AC, Kolev M et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 46, 840-848 (2007).
30. Piguet AC, Semela D, Keogh A et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J. Hepatol. 49, 78-87 (2008).
31. Watson CJ, Friend PJ, Jamieson NV et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67, 505-509 (1999).
32. Chang GJ, Mahanty HD, Quan D et al. Experience with the use of sirolimus in liver transplantation - use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. 6, 734-740 (2000).
33. Toso C, Meeberg GA, Bigam DL et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83, 1162-1168 (2007).
34. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 10, 1301-1311 (2004).
35. Zhou J, Fan J, Wang Z et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J. Gastroenterol. 12, 3114-3118 (2006).
36. Zimmerman MA, Trotter JF, Wachs M et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl. Int. 20, 747-753 (2007).
37. Zimmerman MA, Trotter JF, Wachs M et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 14, 633-638 (2008).
38. Chen YB, Sun YA, Gong JP. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat. Dis. Int. 7, 25-28 (2008).
39. Rizell M, Andersson M, Cahlin C et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J. Clin. Oncol. 13, 66-70 (2008).
40. Decaens T, Luciani A, Itti E et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Hepatology 48(Suppl.), 953A (2008) (Abstract 1453).
41. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26(18), 2992-2998 (2008).
42. Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J. Cancer Res. Clin. Oncol. 135(2), 271-281 (2009).
43. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48(4), 1312-1327 (2008).
44. Thomas MB, Chadha R, Glover K et al. Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110(5), 1059-1067 (2007).
45. Treiber G, Wex T, Rocken C et al. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 132, 699-708 (2006).
46. Newell P, Roayaie S, Schwartz M et al. Mechanisms of Ras pathway activation in HCC patients, and combination therapies blocking Ras (sorafenib) and mTOR pathways (rapamycin) in vivo. Hepatology 48(Suppl.), 983A (2008) (Abstract 1521).
47. Attia S, Holen KD, Thomas JP et al. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin. Adv. Hematol. Oncol. 6, 44-54 (2008).
48. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).